Alphatec Sees Unusually Large Options Volume (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) was the recipient of unusually large options trading on Friday. Stock traders bought 2,902 call options on the stock. This is an increase of 92% compared to the average volume of 1,511 call options.

Alphatec Trading Down 4.2 %

Shares of NASDAQ ATEC traded down $0.41 during mid-day trading on Tuesday, hitting $9.34. 1,271,681 shares of the company traded hands, compared to its average volume of 1,978,316. Alphatec has a 1 year low of $4.88 and a 1 year high of $14.88. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -7.30 and a beta of 1.39. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The business has a 50 day moving average of $10.95 and a two-hundred day moving average of $8.80.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. On average, sell-side analysts anticipate that Alphatec will post -1.08 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ATEC. Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Piper Sandler upped their price target on Alphatec from $12.00 to $13.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Tuesday, January 14th. Needham & Company LLC reissued a "buy" rating and set a $16.00 price target on shares of Alphatec in a research report on Thursday, February 27th. Finally, StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $17.67.

Insider Buying and Selling

In related news, CEO Patrick Miles sold 12,691 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the transaction, the chief executive officer now directly owns 5,857,603 shares of the company's stock, valued at approximately $62,324,895.92. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at $5,379,750.81. This trade represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 337,321 shares of company stock valued at $3,828,060. Corporate insiders own 22.80% of the company's stock.

Institutional Investors Weigh In On Alphatec

Several hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Alphatec by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after acquiring an additional 47,797 shares in the last quarter. American Century Companies Inc. increased its position in Alphatec by 36.5% in the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after purchasing an additional 1,334,780 shares during the last quarter. Royal Bank of Canada increased its position in Alphatec by 171.2% in the 4th quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock worth $29,240,000 after purchasing an additional 2,010,806 shares during the last quarter. State Street Corp increased its position in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after purchasing an additional 287,350 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Alphatec by 11.3% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after purchasing an additional 297,850 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.